Photon-counting CT-optimized features with the OmniTom Elite system include 30 cm field of view scanning, continuous spiral scanning, and an ultra-high-resolution capability of 0.141 mm resolution.
The Food and Drug Administration (FDA) has granted 510(k) clearance for the latest version of the OmniTom Elite system, which has been enhanced with photon-counting CT (PCCT) technology.
The PCCT-optimized features of the device range from advanced image processing and an expanded scope of scanning to helical scanning capability, according to NeuroLogica, a subsidiary of Samsung that manufactures the OmniTom Elite system.
The enhanced OmniTomElite computed tomography (CT) system offers a variety of photon-counting CT features including an ultra-high resolution mode with 0.141 mm resolution and expanded scanning to capture a 30 cm field of view. (Image courtesy of NeuroLogica.)
NeuroLogica said key benefits include access to 0.141 mm resolution with the system’s ultra-high resolution mode, post-reconstruction features such as bone removal and virtual non-contrast, continuous spiral scanning capability and expanded scanning to capture a 30 cm field of view.
“With these new features, the OmniTom® Elite PCD not only offers exquisite image quality and diagnostic capabilities but also ensures a more versatile and efficient imaging process. This is a significant advancement for point-of-care imaging, continuing our commitment to enable clinicians to make a more confident diagnosis due to the improved clinical information,” noted Renaud Maloberti, the vice president and head of mCT business at NeuroLogica.
Can CT-Based AI Provide Automated Detection of Colorectal Cancer?
February 14th 2025For the assessment of contrast-enhanced abdominopelvic CT exams, an artificial intelligence model demonstrated equivalent or better sensitivity than radiologist readers, and greater than 90 percent specificity for the diagnosis of colorectal cancer.
Key Chest CT Parameters for Body Composition May be Prognostic for Patients with Resectable NSCLC
February 11th 2025A high intermuscular adipose index has a 49 percent increased likelihood of being associated with lower overall survival in patients with resectable non-small cell lung cancer (NSCLC), according to new research.
The Reading Room: Racial and Ethnic Minorities, Cancer Screenings, and COVID-19
November 3rd 2020In this podcast episode, Dr. Shalom Kalnicki, from Montefiore and Albert Einstein College of Medicine, discusses the disparities minority patients face with cancer screenings and what can be done to increase access during the pandemic.
Comparative AI Study Shows Merits of RapidAI LVO Software in Stroke Detection
February 6th 2025The Rapid LVO AI software detected 33 percent more cases of large vessel occlusion (LVO) on computed tomography angiography (CTA) than Viz LVO AI software, according to a new comparative study presented at the International Stroke Conference (ISC).
New CT Angiography Study Shows Impact of COVID-19 on Coronary Inflammation and Plaque
February 5th 2025Prior COVID-19 infection was associated with a 28 percent higher progression of total percent atheroma volume (PAV) annually and over a 5 percent higher incidence of high-risk plaque in patients with coronary artery lesions, according to CCTA findings from a new study.